checkAd
    Startseite > Aktien > Corvus Pharmaceuticals > Nachrichten
    Corvus Pharmaceuticals Aktie
    2,1100
     
    USD
    +1,44 %
    +0,0300 USD
    Letzter Kurs 02:00:00 Nasdaq
    2,0900
     
    USD
    300 STK
    Geldkurs 13.05.24
    2,1100
     
    USD
    2.200 STK
    Briefkurs 13.05.24
    ISIN: US2210151005 · WKN: A2AFXS · SYM: CRVS · USA

    Neueste Nachrichten

    Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
    06.05.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
    02.05.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
    02.05.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
    09.04.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    19.03.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
    13.03.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
    12.02.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
    08.02.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
    06.02.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
    23.01.24 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
    02.11.23 · globenewswire · Corvus Pharmaceuticals
    Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
    02.11.23 · globenewswire · Corvus Pharmaceuticals